<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01210040</url>
  </required_header>
  <id_info>
    <org_study_id>10.55</org_study_id>
    <secondary_id>1U01HD061234-01A1</secondary_id>
    <nct_id>NCT01210040</nct_id>
  </id_info>
  <brief_title>Long-term Iron Supplements and Malaria Risk in Early Pregnancy: a Randomized Controlled Trial</brief_title>
  <acronym>PALUFER</acronym>
  <official_title>Malaria Risk Prior to and During Early Pregnancy in Nulliparous Women Receiving Long-term Weekly Iron and Folic Acid Supplementation (WIFS): a Non-inferiority Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Liverpool School of Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute of Tropical Medicine, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Manchester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut de Recherche en Sciences de la Sante-Direction Regionale de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Muraz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Liverpool School of Tropical Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized double-blind controlled trial will be carried out in which young, nulliparous
      (having never given birth) women will be randomly assigned to receive weekly supplementation
      with either iron and folic acid or folic acid alone. Women will be followed-up weekly up to
      18 months. Women who become pregnant will be followed-up until delivery. Malaria risk in both
      groups will be compared by assessing the prevalence of peripheral parasitaemia at the first
      antenatal clinic visit for pregnant women and at the end of the first malaria transmission
      season for non-pregnant women. The incidence of clinical malaria will be assessed by active
      and passive case detection throughout the follow-up period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of peripheral parasitaemia at first antenatal clinic visit (13-16 weeks gestation)</measure>
    <time_frame>Nov 2013</time_frame>
    <description>Completed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>a) In the pregnant cohort: Prevalence of iron deficiency at first antenatal visit</measure>
    <time_frame>Sept 2013</time_frame>
    <description>Completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a) In the pregnant cohort: Prevalence of anaemia at first antenatal clinic visit</measure>
    <time_frame>Sept 2013</time_frame>
    <description>Completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a) In the pregnant cohort: Incidence of clinical malaria during the first and subsequent trimesters</measure>
    <time_frame>Jan 2014</time_frame>
    <description>Completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a) In the pregnant cohort: Incidence of adverse pregnancy outcomes</measure>
    <time_frame>Jan 2014</time_frame>
    <description>Completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a) In the pregnant cohort: Mean birth weight and prevalence of low birth weight (&lt;2500g)</measure>
    <time_frame>Jan 2014</time_frame>
    <description>Completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a) In the pregnant cohort: Mean gestational age at delivery</measure>
    <time_frame>Jan 2014</time_frame>
    <description>Completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a) In the pregnant cohort: Prevalence of placental malaria</measure>
    <time_frame>Jan 2014</time_frame>
    <description>Completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a) In the non-pregnant cohort: Prevalence of peripheral parasitaemia during the first rainy season after at least six months of supplementation</measure>
    <time_frame>Nov 2012</time_frame>
    <description>Completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a) In the non-pregnant cohort: Incidence of clinical malaria</measure>
    <time_frame>Nov 2013</time_frame>
    <description>Completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a) In the non-pregnant cohort: Incidence of gastrointestinal adverse events</measure>
    <time_frame>Nov 2013</time_frame>
    <description>Completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a) In the non-pregnant cohort: Prevalence of iron deficiency after at least 18 months supplementation</measure>
    <time_frame>Nov 2013</time_frame>
    <description>Completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a) In the non-pregnant cohort: Prevalence of anaemia after at least 18 months supplementation</measure>
    <time_frame>Nov 2013</time_frame>
    <description>Completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a) In the non-pregnant cohort: Adherence to supplementation</measure>
    <time_frame>Nov 2013</time_frame>
    <description>Completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a) In the non-pregnant cohort: Acceptability of weekly supplementation</measure>
    <time_frame>June 2013</time_frame>
    <description>Completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In the non-pregnant cohort: Prevalence of bacterial vaginosis at end assessment</measure>
    <time_frame>Nov 2013</time_frame>
    <description>Completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a) In the non-pregnant cohort: Prevalence of bacterial vaginosis at end assessment</measure>
    <time_frame>Nov 2013</time_frame>
    <description>Completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a) In the non-pregnant cohort: Prevalence of bacterial vaginosis at first antenatal visit</measure>
    <time_frame>Nov 2013</time_frame>
    <description>Completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a) In the non-pregnant cohort: Prevalence of iron deficiency at key study visits</measure>
    <time_frame>Nov 2013</time_frame>
    <description>Completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a) In the non-pregnant cohort: Prevalence of peripheral parasitaemia at end assessment</measure>
    <time_frame>Nov 2013</time_frame>
    <description>Completed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1959</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Folic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.8mg of Folic Acid given weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Folic Acid and Iron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.8mg Folic Acid and 60mg Iron given weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Folic Acid</intervention_name>
    <description>2.8mg</description>
    <arm_group_label>Folic Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Folic Acid and Iron</intervention_name>
    <description>60mg Iron and 2.8mg Folic Acid</description>
    <arm_group_label>Folic Acid and Iron</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  At least 15 and less than 25 years old at enrolment

          -  Never given birth

          -  Resident within the Demographic Surveillance System (DSS) area

          -  Willing to adhere to the study requirements (including weekly observed drug intake)

          -  Provision of written informed consent (if non emancipated minor by guardian/parent
             with minor's assent

        Exclusion Criteria:

          -  No menses for &gt;3 months and/or palpable uterus or positive pregnancy test if history
             unclear

          -  Concurrent enrolment in another study

          -  Intention to move out of the study area for more than 2 months within the next 18
             months

          -  Any significant illness at the time of screening that requires hospitalization,
             including clinical signs of severe anaemia (conjunctival or mucosal pallor,
             tachycardia, respiratory distress)

          -  History or presence of major clinical disease likely to influence pregnancy outcome
             (sickle cell disease, diabetes mellitus, severe renal or heart disease, open
             tuberculosis, epilepsy)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard J BRABIN, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Liverpool School of Tropical Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sabine GIES, MD, MTropMed, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Unit Nanoro (CRUN)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute de Recherche en Sciences de la Sante, Direction Regionale de l'Ouest (IRSS-DRO) - / Centre Muraz</name>
      <address>
        <city>Bobo-Dioulasso 01</city>
        <zip>01 B.P. 545</zip>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2010</study_first_submitted>
  <study_first_submitted_qc>September 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2010</study_first_posted>
  <last_update_submitted>March 18, 2014</last_update_submitted>
  <last_update_submitted_qc>March 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pregnancy</keyword>
  <keyword>Iron deficiency</keyword>
  <keyword>Iron supplementation</keyword>
  <keyword>Burkina Faso</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

